ALL ABOUT Tapinarof 1% cream / Vtama for Dermatology Residents EXPLAINED by Dermatologist

IADVL Textbook of DERMATOLOGY https://amzn.to/34HjMvm Rooks https://amzn.to/3B7I5ie Bolognia https://amzn.to/3uxcxRy Fitzpatrick https://amzn.to/3rxvBNz Andrews https://amzn.to/3rwDpiz Habif https://amzn.to/3B5l8Mp Moschella & Hurley'S Dermatology https://amzn.to/3GxpM74 Compendium of Dermatology https://amzn.to/3ufTnxB Leprosy: Jopling New https://amzn.to/3J7gUqr IAL https://amzn.to/336GWe8 STD: King Holmes https://amzn.to/3HB2XR4 IASTD NEW HANDBOOK https://amzn.to/3GugEQx OLD https://amzn.to/3Li3I3O Dermato Therapeutics: Wolverton https://amzn.to/3HyTZUJ Systemic Drugs in Dermatology: https://amzn.to/3V4vHLp Lebwohl https://amzn.to/3grVOXl Dermato Pathology: Levers Dermatopathology https://amzn.to/3J9iAj5 Weedons Dermatopathology https://amzn.to/3sqnGAX Venkatram mysore https://amzn.to/3B2BoxR Clinical Dermatology: Ward rounds in derma https://amzn.to/3uxcl4P https://t.me/+JNaxOzYMYykxYjVlDermato... Residents, Join & share the above link among your Friends & Colleagues for Derma Thesis Help, Latest Journal Updates & Treatment related discussions, Theory & Practical Exam related Support in Dermatology CONCEPTUAL DERMATOLOGY | COMPREHENSIVE Lectures / Classes for DERMA RESIDENTS | Dr Maddineni Srinivas | DrMSD | DermaGyaan | Post Graduate DVL VIDEOS ALL ABOUT Tapinarof cream for Dermatology Residents ALL ABOUT Tapinarof 1% cream / Vtama for Dermatology Residents EXPLAINED by Dermatologist TIME STAMPS: Intro: 00:00 Introduction – Tapinarof (VTAMA) 1% is a first‑in‑class, non‑steroidal AHR agonist; once‑daily topical approved in the USA. Uses/Indications – Adult plaque psoriasis; atopic dermatitis (AD) ≥2 years (FDA Dec 2024); head‑to‑toe use. How it works/MOA – Activates AHR→ARNT, boosts NRF2, ↑filaggrin/loricrin, ↓IL‑17; calms inflammation and repairs barrier. Contraindications – Hypersensitivity to components; not for oral, ophthalmic, or intravaginal use. Benefits/Pros – Strong efficacy, rapid itch relief, low systemic absorption, sensitive‑site friendly, remittive effect (~4 mo). Disadvantages/Cons – Limited head‑to‑head data; access/cost may need prior authorization; long‑term real‑world data evolving. Side effects and risks – Folliculitis (~20%), nasopharyngitis (~10%), contact dermatitis (~5%), headache/pruritus—generally mild. Use in special populations – AD ≥2y; pregnancy/lactation data limited; elderly similar; no hepatic/renal dose adjustment. My Derma Group Links https://linktr.ee/Crack_Derma_with_DrMSD 👍 Telegram channel link- https://t.me/DrMaddineniSrinivas 👍 Instagram -   / crack_derma_with_dr.msd_skindr   👍 Follow this link to join my WhatsApp group: https://chat.whatsapp.com/Ei4RaVD9IkU... Twitter :   / derma_by_drmsd   Pintrest :   / _saved   For all my FREE VIDEO explanations, Follow my ,Channels, These are "ALL" https://linktr.ee/Crack_Derma_with_DrMSD Subscribe to Our Channel for More Updates:    / drmaddinenisrinivasdermatologistdrmsd   DrMSD,Dr Maddineni Srinivas Dermatologist,https://t.me/drmaddinenisrinivas,derm... lectures,dermatology oneliners,crack derma with drmsd,DermaGyaan,Dr Maddineni Srinivas,dr maddineni srinivas dermatologist,derma residents lectures,worldwide derma discussion,derma faculty,tapinarof cream,vtama cream,USA FDA,psoriasis,eczema,atopic dermatitis #CrackDermaWithDrMSD #DrMaddineniSrinivas WORLD_WIDE_DERMA